Study on Point Mutations of K-ras Gene in Non-small Cell Lung Cancer in Guangxi

Abstract

Background and objective Recent studies indicated that non-small cell lung cancer (NSCLC) patients with mutant K-ras were resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study is to explore the relationship between the mutation of K-ras gene and NSCLC in Guangxi by detecting the point mutations in codon 12, 13 and 61 of K-ras gene in NSCLC. Methods The point mutations in codon 12, 13 and 61 of K-ras gene were detected by single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products and DNA sequencing analysis in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. Results No point mutation in codon 12, 13 and 61 of K-ras gene was found in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. In this study, the mutation frequency of K-ras gene in NSCLC was 0 (0/105). Conclusion The high proportion of K-ras gene in wild-type indicates that patients with NSCLC in Guangxi could take more benefits from the therapy with EGFR-TKIs.

Keywords

• Lung neoplasms
• K-ras gene
• Point mutation